Microbiota‐related metabolites fueling the understanding of ischemic heart disease

Abstract

Up-to-date knowledge of gut microbial taxa associated with ischemic heart disease (IHD). Microbial metabolites for mechanistic dissection of IHD pathology. Microbiome-based therapies in IHD prevention and treatment. Ischemic heart disease (IHD) has caused a major burden on public health due to its high morbidity and mortality [1, 2]. IHD is commonly also referred to as coronary heart disease (CHD) or coronary artery disease, meaning a heart problem characterized by narrowed or blocked coronary arteries with reduced blood flow to the heart muscle (https://www.cdc.gov/heartdisease/coronary_ad.htm). Depending on the clinical manifestations of the disease, IHD can be classified into stable or chronic IHD and acute coronary syndrome reflecting an imbalance between myocardial oxygen demand and supply (https://www.nhs.uk/conditions/coronary-heart-disease). Patients who suffer from IHD are frequently accompanied by common risk factors for many years before overt IHD, including obesity, type 2 diabetes (T2D), and metabolic syndrome [3], calling for more specific and effective strategies for IHD prevention and intervention. From the outcome of recent epidemiological, physiological, integrated omics-based studies, followed by the findings from both animal and cellular investigations, it shows that a great proportion of the links between the environmental influences and human IHD may be contributed by microbial communities (termed gut microbiome) [4]. It has been revealed that the collection of all intestinal bacterial genes has more than an order of magnitude higher gene numbers than the human genome [4]. The total amount of gut bacteria exceeds 1014 microorganisms, whereas the gut virus has even more orders of magnitude higher quantity than that of bacteria [5]. The gut microbes, including bacteria, archea, virus, and unicellular eukaryotes, may collectively provide a repository of information characterizing the IHD development [6]. In the meanwhile, the various enzymes encoded by gut microbes may participate in pathways of producing numerous metabolites, which may via the blood circulation impact systemic and myocardial metabolism that are associated with IHD [7]. Therefore, it is reasonable to believe the strong involvement of gut microbes in the IHD development. In the past two decades, rapid development in next-generation sequencing technology and bioinformatic databases and tools allowed us to gain deeper knowledge of the relationships between gut microbial compositions, functional potentials, and host phenotypes, which has greatly sped up the field from cohort-based towards personalized understanding [8]. Yet, the gap still remains between basic science and clinical translation. For instance, specific taxa is lacking for the precise diagnosis of IHD [9], the causality of microbiome on IHD is poorly understood [10], and microbiome-based therapy in patients has not yielded satisfying efficiency [11]. Therefore, it is of great importance to explore additional mechanistic involvement of gut microbiota in the IHD development, either based on observational findings from populational studies or evidence from experimental validations. To determine the impact of gut microbiota on IHD development, the microbiota-related metabolites may play an important and nonignorable role by mediating the alterations of microbial functionalities on host phenotypic changes. In this review, we summarize recent advances in the IHD-linked alterations in microbiome, not only with a focus on the taxa of bacteria (Figure 1 and Supporting Information: Table 1), but also with a particular emphasis on the microbiota-related metabolites that regulate the initiation, escalation, and onset of IHD (Figure 2 and Table 1). We also provide insights into the updates and perspectives of microbiome-based therapies against IHD development (Figure 3). In addition to that, we point out the gut virome/phageome as an emerging possibility in interfering the gut bacterial structure or function, thereby complementing therapeutic strategy on IHD (Figure 2). Patients with different types of IHD are often found to be associated with gut dysbiosis at multiple resolutions (Figure 1). However, due to the fact that patients with atherosclerosis are frequently found to have prior clinically silent metabolic dysregulations for many years, it is therefore a major challenge to delineate the putative impact of gut bacterial imbalance on early-stage metabolic dysfunction from IHD onset. In addition to that, most of the IHD patients are always heavily medicated on its various comorbidities, such as obesity, T2D, and so on, making it even more challenging to decode the gut microbial alterations directly linked to IHD itself without accounting for the dysbiosis induced by its premorbidities and comorbidities. In 2017, Cui et al. [12] found that the abundance of phylum Bacteroidetes and Proteobacteria in patients with IHD were lower than that in the controls without adjusting for any medications or comorbidities. In addition, the class Bacteroidia, belonging to phylum Bacteroidetes, was significantly decreased in the IHD patient group compared with the control group. In contrast, phylum Firmicutes and Fusobacteria was higher than that in the controls [12]. At the family level, in 2019, Liu et al. [13] reported that Lachnospiraceae and Ruminococcaceae decreased significantly in IHD patients. Meanwhile, they found that Proteobacteria phylotypes such as Streptococcus, Haemophilus, and Granulicatella increased higher in the group with more severe heart disease by multiple comparisons among its subgroups [13]. In addition, they found that the abundance of the co-abundance group 17, which contained several Gram-negative bacteria, such as Veillonella, Haemophilus, and Klebsiella, increased with IHD severity [13]. According to the previous findings, these bacteria trigger the innate immune response via lipopolysaccharide (LPS) production and elicit a subsequent inflammatory reaction [14]. At the genus level, Jie et al. [9] found that there was a relative reduction in Bacteroides and Prevotella, and enrichment in Streptococcus and Escherichia in gut bacteriome of patients with atherosclerotic cardiovascular disease (ACVD). The abundance of Enterobacteriaceae and the bacteria that are often found in the oral cavity, such as Streptococcus spp., Lactobacillus salivarius, Solobacterium moorei, and Atopobium parvulum, were also higher in patients with ACVD than in healthy controls. In contrast, butyrate-producing bacteria including Roseburia intestinalis and Faecalibacterium prausnitzii were depleted in the ACVD gut bacteriome. It is worthwhile to note that the gut microbiota also showed differences in network structure between ACVD and healthy individuals. For instance, it was found that ACVD microbiome is characterized by a negative correlation between ACVD-depleted commensals Bacteroides spp. and aerobes Streptococcus spp., which is intriguingly absent in normal control gut bacteriome. These results demonstrated profound imbalances in the composition and inter-species relationship in the gut microbiome of ACVD patients as compared with healthy controls [9]. Of special interest is the impact of major disease confounders on IHD microbiome analysis, including promorbidities, comorbidities, and multidrug interventions, which have gained attention. A recent work focused on characterizing the altered microbial features along the nature history of IHD, including disease initiation and escalation, while accounting for the effects of medication and lifestyle, on different IHD stages. It was reported long before the early clinical manifestation of IHD, the major microbial and metabolic alterations had already begun. The researchers additionally by using machine learning algorithms identified deconfounded IHD-specific microbiome and metabolome features, which likely provide better capacity in IHD subgroup classification than that of the conventional IHD biomarkers. The IHD-specific bacterial features are composed of 23 species including Acinetobacter, Turcimonas, and Acetobacter depleted in IHD patients, and 8 species enriched in IHD which contains 2 species in Burkholderiales order [10]. One of the two species in Burkholderiales order was reported as a possible cause of endocarditis [15]. This work highlighted the importance of accounting for interactions by confounders when analyzing microbiome data in complex noncommunicable diseases. In another Israeli cohort, Yeela et al. [16] reported that 20 bacterial genomes significantly enriched in either the patients with acute coronary diseases (ACS) or the control individuals by adjusting the confounders including clinical parameters and multidrug usage. They found that butyrate-producing bacteria such as Clostridium, Anaerostipes hadrus, Streptococcus thermophilus, and Blautia decreased, whereas the abundance of Odoribacter splanchnicus and Escherichia coli increased in ACS patients. In addition to known bacterial features, they found a previously unknown bacterial species of the Clostridiaceae family that was depleted in ACS [16]. Interestingly, researchers from both groups found that butyrate producers decreased in IHD patients, which may lead to the reduced production potential of short-chain fatty acids (SCFAs). As for acute myocardial infarction (AMI), Han et al. [17] recruited 30 in-hospital AMI patients in China and found bacteria belonging to the phyla Actinobacteria, Cyanobacteria, Proteobacteria, and Verrucomicrobia are enriched in AMI gut microbiome, whereas the phyla Fusobacteria and Tenericutes decreased. In addition, they reported that the patients who suffered the AMI caused by left anterior descending coronary stenosis are characterized by enriched Ruminantium group, Comamonadaceae, Comamonas, and unknown species belonging to the MollicutesRF9 order [17]. This study, although without considering the confounding effects of polypharmacy and lifestyle in a relatively small cohort, points to the potential for gut microbial involvement in AMI caused by coronary branch vessel stenosis. Vast studies have revealed that the compositional and structural aberrancies in gut microbiota characterize IHD patients. However, the underlying mechanistic information of microbiota-IHD associations remains unsystematically reviewed. In fact, the gut microbiome, as a genetic repository, is an immense factory that can release or synthesize overwhelming numbers of chemicals needed for the communication between gut commensals and host (Table 1). In the following section, we selectively summarize the IHD-specific bacterial messengers and their impacts on IHD pathophysiology (Figure 2). Dietary factors such as choline and carnitine are closely related to TMAO, which is proved as an independent risk factor for IHD [48-50]. TMAO comes from many sources, such as egg, fish, red meat, and so on [51]. In 2013, Hazen and colleagues [48] found that TMAO was an independent risk factor for IHD and subsequent experiments demonstrated that TMAO levels were associated with death and nonfatal myocardial infarction [48, 52, 53]. The precursor of TMAO is trimethylamine (TMA), which is produced by intestinal microorganisms from nutrients containing l-carnitine or phosphatidylcholine [50]. TMA produced by intestinal microorganisms can enter the host circulation and reach hepatocytes. In the liver, kidney, and other tissues, TMA is metabolized by flavin-containing monooxygenase (FMO), which is encoded by FMO gene [54, 55]. Higher production of TMAO will affect lipid metabolism and reduce cholesterol clearance by inhibiting the synthesis of bile acids (BAs) [56, 57]. This may be because TMAO induces the expression of two scavenging receptors (CD36 and scavenger receptor A) on the cell surface which lead to inhibit the reverse transport of cholesterol and the accumulation of cholesterol in macrophages [58]. Moreover, TMAO can also induce calcium release and platelet hyperreactivity, thereby affecting the IHD development [59]. TMAO can upregulate inflammatory factors such as tumor necrosis factor α (TNF-α), interleukin (IL)-6, IL-18 through the activation of TXNIP-NLRP3 [60]. It can boost the expression of vascular cell adhesion molecule 1 and monocyte adhesion, which can lead to plaque development [61]. The gut microbial composition is a major factor that impacts TMAO production. Gwen's study identified a total of 102 genomes from 36 species classified as Firmicutes, Proteobacteria, and Actinobacteria [51] that influenced the production of TMA. Another study found that eight species representing phylum Firmicutes and Proteobacteria, and six genera consume more than 60% of choline presented in the media, which subsequently led to a remarkable production of TMA [18, 62]. Additional experiments have also expanded the TMA-producing bacteria to Ruminococcus [63]. In addition, the taxonomic identification of TMA-producing gut bacteria, biosynthetic genes, and gene clusters (BGCs) responsible for the production TMA have been reported. Two dominant TMA synthesis pathways have been extensively studied; these are as follows: (1) using choline as a substrate via the choline TMA-lyase (CutC) and its activator CutD [64]; (2) acting on carnitine through a two-component Rieske-type oxygenase/reductase (CntA/B) [65]. In addition, the enzyme complex YeaW/X has also been shown to take part in the TMA synthesis [66]. The γ-butyrobetaine (γBB)-specific BGCs are six adjacent genes consisting of one acyl-CoA dehydrogenase (gbuA), two acyl-CoA transferases (gbuB, gbuC), a ubiquinone oxidoreductase (gbuD), a betaine/carnitine/choline transporter (gbuE), and one acyl-CoA thioester hydrolase (gbuF), among which four genes were identified as necessary and sufficient for TMA production in the non-native E. coli host: gbuA, gbuB, gbuC, and gbuE [67]. Although TMAO is the most widely studied independent risk factor related to IHD, more microbiota-dependent risk factors have been found. For instance, trimethyllysine (TML), a precursor of the synthesis of carnitine, which can be metabolized to proatherogenic TMA, is a strong predictor of incident IHD, independent of TMAO [68]. Another proatherogenic agent, γBB, which is an intermediate in gut microbial transformation of carnitine to TMA, was also found to be closely related to the risk of IHD in clinical cohort (n = 2918). Furthermore, N,N,N-trimethyl-5-aminovaleric acid (TMAVA), which was derived from TML through the gut microbial metabolism, was elevated with gradually increased risk of cardiac mortality and transplantation in a prospective heart failure cohort (n = 1647) [69]. Zhao et al. [69] found that TMAVA increased significantly, especially in patients with hypertension, which may lead to cardiac hypertrophy. In addition, they supplemented mice on a high-fat diet for 12 weeks. They discovered that heart weight was increased in the TMAVA-treated mice, compared with the untreated controls, which suggested that TMAVA aggravates cardiac hypertrophy and dysfunction induced by heart failure. They also found that TMAVA treatment leads to myocardial lipid accumulation and carnitine reduction in plasma and myocardium. They supposed that TMAVA functions through γBB hydroxylase (BBOX) by mice experimenting with BBOX deficiency [69]. In conclusion, TMAO and other related precursors in its synthetic pathway, play an important role in the occurrence and development of IHD, and relevant pathways remain to be further explored. SCFAs including acetate, propionate, and butyrate are fermented from monosaccharides and are the main bacterial products [70, 71]. Acetate and propionate are mostly produced by the phylum Bacteroidetes, whereas butyrate is mainly produced by the phylum Bacteroidetes and Firmicutes [72, 73]. Research by Jie et al. [9] showed that the gut microbiome of IHD patients is characterized by a reduction in Roseburia and Eubacterium, two known producers of butyrate. Consistently, they found the functional potential for butyrate production reduced in IHD patients [9]. SCFAs have positive effects including regulating intestinal pH, decreasing body weight, improving insulin sensitivity, and promoting intestinal motility [73, 74]. The SCFAs can also reduce blood lipid levels by transferring cholesterol to the liver and blocking cholesterol synthesis [75]. SCFAs are transported by specific monocarboxylate transporters through the intestine into the blood. SCFAs work by acting as a ligand for the G-protein-coupled receptors (GPR43 and GPR41) [76, 77]. These receptors play a vital role in the regulation of energy consumption and expenditure, and immune response. Furthermore, another research reported that there was a strong negative correlation between butyrate-producing genes and C-reactive protein (CRP) levels [78], which has been reported to be closely related to the occurrence of IHD. The gut SCFA-producing bacteria have been shown to be less abundant in certain IHD and hypertension patients [78, 79]. Both SCFA-producing bacterial features and SCFAs are considered as a protective element in IHD development. Thus, targeted strategies enriching the SCFAs and its producers are potential therapeutic means for IHD preventions. Gut microbiota is one of the main contributors in regulating circulating BAs [80, 81]. Primary BAs are synthesized by the oxidation of cholesterol in the liver and secreted into the intestine as taurine- or glycine-conjugated forms at C24 to dissolve lipids for absorption through the rate-limiting enzyme cholesterol 7-α-hydroxylase (CYP7A1) [82]. Primary BAs (cholic acid and chenodeoxycholic acid) are converted into secondary BAs (deoxycholic acid, lithocholic acid [LCA], ursodeoxycholic acid [UDCA], and so on) through microbial dehydroxylation [83]. About 95% of BAs are reabsorbed and recycled from the intestine, except for LCA and UDCA [84]. BAs can act as ligands activating nuclear receptor farnesoid X receptor and Takeda G-protein-coupled receptor-5 (TGR5) [82, 85]. Through activating the two receptors, BAs can reduce the serum cholesterol level [86]. Moreover, upon activation of TGR5, BAs can also protect LPS-induced inflammation [87]. More specifically related to IHD development, the study led by Mayerhofer et al. [88] demonstrated that BAs reduce heart rate and regulate vascular tension via regulating channel conductance and calcium dynamics. Moreover, they found that the primary to secondary BAs ratio is positively correlated with the level of circulating cholesterol in patients with heart failure and IHD development [88]. Although most studies focus on describing the associations between gut microbes and circulating BAs, a deeper understanding towards the regulator of gut microbiota responsible for BAs metabolism is sparse. As a notable example, Wang et al. [89] demonstrated the gut bacterial structural variations (SVs) greatly determine the BAs metabolism. Systematically characterizing two types of SVs, deletion and variable SVs, in the human gut microbiome from two cohorts consisting of 1437 participants, and associating the SVs profile to circulating BAs, allowed the investigators to identify the genetic regions in specific bacterial genomes that are responsible for BAs regulation. More interestingly, such a strategy also identifies putative regions encoding BA-metabolizing enzymes, although experimental evidence is still lacking due to the big challenge in isolating bacterial strains carrying the identified regions. We assume that if the gut microbial features (taxas, functional potentials, and SVs), which is related to BAs metabolism, are in a state of imbalance, IHD is developed. Therefore, the BA-relevant bacterial functions, receptors, and pathways need to be explored and may be targeted for therapeutic intervention of IHD. The depletion of butyrate-producing bacteria may not only cause reduction of butyrate but also lead to intestinal mucosal barrier dysfunction and increase the passive leakage of microbial toxins, such as LPS and other receptors of the innate immune system, leading to inflammation [90, 91]. Recently, Awoyemi et al. [92] reported that increasing levels of LPS-binding protein associated with high risk of IHD. Intestinal leakage may also lead to the translocation of LPS [93]. Several studies have reported that hexa-acylated LPS but not penta-acylated LPS can lead to systematic inflammation [94, 95]. Therefore, we highlight that hexa-acylated LPS may be a potential target IHD treatment. Gut microbiota can lead to IHD development via regulating our immune system. IHD is a chronic inflammatory disease, whereas AMI is suspected to be associated with acute inflammation [96, 97]. In our body, oxidized low density lipoprotein (oxLDL) can promote atherosclerosis and inflammation by activating endothelial cells, macrophages, and T cells. Macrophages can promote generation of inflammatory factors (TNF-α, IL-6, IL-18, and IL-37) by devouring oxLDL and leading to IHD development as a consequence [98, 99]. The composition of gut microbiota can strongly influence body's immune system. The study by Mikelsaar et al. [100] reported that the quantity of Lactobacillus reuteri, which exists in the intestine, is associated with high levels of white blood cells. Furthermore, Low Oscillibacter, Faecalibacterium, and Ruminococcus are correlated with high CRP level [101, 102]. Besides, germ-free mouse models showed that the development of T cells is directly influenced by gut microbiota, particularly the differentiation of T helper 17 cells (Th17) [103-105]. The research by Gil-Cruz et al. [60] reported that myocarditis may depend on specific Th17 cells derived from gut microbiota. They additionally found that Bacteroides thetaiotaomicron and B. faecis can promote inflammatory myocardiopathy [60]. Furthermore, butyrate produced by gut bacteria promotes the forkhead box P3 (Foxp3+) regulatory T cell induction [106], as well as acts on the GPR43 and GPR41 for affecting immune system [76, 107]. PAGln, a product from microbial fermentation of dietary phenylalanine followed by conjugation to glutamine, has been reported to be associated with IHDs and major adverse cardiovascular events independently [108]. Among patients with carotid plaque, plasma level of PAGln was significantly lower in protected phenotype rather than other more severe phenotype. Therefore, it is considered that lower PAGln may contribute to plaque stability in carotid atherosclerosis [109]. As for patients with IHD, Liu et al. [110] reported an independent association between plasma PAGln levels and the coronary atherosclerotic burden. Patients with the higher PAGln levels had higher risks of obstructive IHD and higher coronary lesion complexity [110]. Mechanically, genetic engineering studies followed by microbial transplantation showed that PAGln contribute to the thrombosis potential by accelerating platelet clot formation, calcium release, and responsiveness to multiple agonists. By using multiple genetic and pharmacological screening, PAGln was found to interact with G-protein-coupled receptors, in particular adrenergic receptors (ADRs), including α2A, α2B, and β2-ADRs, which highly present on human platelets. ADRs are crucial for cardiovascular functions and closely related to cardiovascular events [111] and platelet activity [112]. Selective ADR inhibitors can reduce the platelet hyperreactivity induced by PAGln and the acceleration rate of thrombosis in vivo [43]. Similar to TMAO, PAGln and PAGln-releasing gut microbes appear to be the other potential targets for treating IHD in future efforts. Among the well-known microbiota-related metabolites, two protein-bound uremic toxins, p-cresol sulfate (PCS) and indoxyl sulfate (IS), are associated with cardiovascular events [113-115] and cardiovascular stiffening [116] in patients with chronic kidney disease (CKD). Indeed, CKD patients are often found to display a substantial increase in cardiovascular disease [117]. In the rat CKD model, etiological evidence has been described that PCS and IS may, via activating the coagulation and pro-inflammatory pathways, contribute to the onset and development of calcification in the vessel wall [118] (Table 1). However, it is important to note that conflicting results exist for the absence in associations between PCS, IS, and cardiovascular outcomes in patients undergoing hemodialysis [119]. Caution is required in the causal interpretation of PCS and IS in IHD development. Considering the high mortality and morality of IHD in modern society, clinical translation of the identified IHD-specific microbiota-dependent targets is urgently needed. In response to the arising evidence indicating gut microbiota plays a crucial role in IHD, more and more attention has been paid to the therapeutic strategies targeting gut microbial modulation. In the following section, we will highlight several tools and strategies to modulate gut microbial community and their potential in IHD intervention (Figure 3). FMT allows for the nutritional enrichment or depletion to the host microbiota, inhibits the growth of pathogenic bacteria, and regulates the host's immune system by transplanting and recolonizing live functional bacterial community from healthy donors into the patient's gastrointestinal tract [120]. FMT is the most fundamental intervention for intestinal microbiota and it is also an established and widely accepted method for the treatment of recurrent Clostridium difficile infection [121]. Although it has been shown that obese individuals who receive FMT from lean donors gained enhanced insulin sensitivity and improved phenotypic parameters related to metabolic syndromes [122], the outcomes are highly varied among studies. For instance, the TMAO levels in individuals with metabolic syndrome are unexpectedly not associated with FMT from a single vegan donor, whereas the gut microbial composition of recipients changes towards that of vegan's, pointing to the importance of big sample size and prolonged follow-up periods in FMT to get desired effects. In addition to the unremarkable changes in TMAO production upon FMT, recent study also reported that transplanting drug-resistant E. coli led to the death of one patient [123], raising the safety concerns of FMT for clinical use. It must be mentioned that challenges in FMT still exists, including the knowledge about optimal conditions for anaerobic handling of donor stools, the incompatibility between recipients and donors, as well as the instability in the survival and recolonization of donor bacteria in recipients’ intestinal tract. Broad-spectrum antibiotics are commonly used in early experiments targeting the intestinal microbiota for IHD. In 2004, the study by Conraads et al. [124] evidenced that broad-spectrum antibiotics reduces the biomarker of systematic inflammation in patients with heart failure, but not specifically focused on clinical symptoms. Galla et al. [125] found that minocycline and vancomycin intervention remarkably increased systolic blood pressure in salt-sensitive rats and decreased systolic blood pressure in spontaneously hypertensive rats. Rune et al. [126] showed in ApoE-deficient mice, ampicillin intervention could reduce blood low-density lipoprotein and very low-density lipoprotein levels. It is interesting to see in the recent study, the oral administration of broad-spectrum antibiotics increased the mortality of myocardial infarction murine model [127]. This is contrary to the previously reported results that oral vancomycin or a mixture of streptomycin, neomycin, polymyxin B, and bacitracin can reduce myocardial infarction size and improve cardiac function [128, 129]. In trials on patients, outcomes also vary, where some studies showed beneficial effects of antibiotics on IHD [130], whereas others did not. The 10-year follow-up data from the Claricor trial showed an increase in cardiovascular death in patients with stable CHD treated with clarithromycin [131]. Therefore, treating IHD with antibiotics remains controversial. Considering these safety problems and the lack of reliable clinical consequences in many trials, antibiotics should be used with caution in future studies aiming at re-structuring intestinal microbiome of IHD. Probiotics can functionally and compositionally interfere with or modulate intestinal microbiota, subsequently activating the immune system and conferring a health benefit [132]. Common probiotics, which have been widely used in clinical practice include Lactobacillus and Bifidobacterium [133, 134]. Prebiotics, which can stimulate the activity of probiotics, are substrates selectively utilized by the host microorganisms. Most prebiotics are carbohydrates, which can induce the increase in SCFAs and improve metabolic health [134, 135]. Animal models have already suggested that some probiotics and prebiotics such as Lactobacilli and inulin can slow down atherosclerosis. Rats treated with Lactobacillus plantarum 299v before coronary artery ligation reduced myocardial infarction area and improved heart function [129]. Mohania et al. [136] found that deposition of cholesterol and TAGs in liver and aorta were significantly reduced in rats fed with probiotic dahi. Another study found that obese volunteers who received 20 g/day of inulin-propionate ester have reduced pro-inflammatory interleukin-8 levels compared with those who received cellulose, whereas inulin had no impact on the systemic inflammatory markers [137]. These observations suggested that probiotics and prebiotics may have therapeutic capacity of reducing hyperlipidemia and diet-induced hypercholesterolemia. In patients with chronic systolic heart failure that was submitted to a 3-month daily oral supplementation of Saccharomyces boulardii (1 g per day) present an improvement in left ventricular ejection fraction and a reduction on le